middle.news

OncoSil’s PANCOSIL Trial Unveils Safer, Smarter Pancreatic Cancer Treatment

9:11am on Thursday 18th of September, 2025 AEST Healthcare
Read Story

OncoSil’s PANCOSIL Trial Unveils Safer, Smarter Pancreatic Cancer Treatment

9:11am on Thursday 18th of September, 2025 AEST
Key Points
  • First CT-guided percutaneous OncoSil™ delivery for pancreatic cancer
  • 90% technical success rate with manageable serious adverse events
  • Median overall survival of 20.6 months versus historical 13 months
  • Plans for expanded regulatory approvals in FY26
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about OSL
OPEN ARTICLE